Novartis Gets Swiss Approval For First Malaria Drug For Babies

Swissmedic, the Swiss Agency for Therapeutic Products, approved Novartis AG’s (NYSE:NVS) Coartem (artemether-lumefantrine) Baby on Tuesday. This marks the first malaria medicine specifically approved for newborns and young infants. The new treatment, also known as Riamet Baby in some countries,…